Constitutive activity of the dopamine (D5 ) receptor, highly expressed in CA1 hippocampal neurons, selectively reduces CaV 3.2 and CaV 3.3 currents

Br J Pharmacol. 2023 May;180(9):1210-1231. doi: 10.1111/bph.16006. Epub 2023 Jan 2.

Abstract

Background and purpose: CaV 3.1-3 currents differentially contribute to neuronal firing patterns. CaV 3 are regulated by G protein-coupled receptors (GPCRs) activity, but information about CaV 3 as targets of the constitutive activity of GPCRs is scarce. We investigate the impact of D5 recpetor constitutive activity, a GPCR with high levels of basal activity, on CaV 3 functionality. D5 recpetor and CaV 3 are expressed in the hippocampus and have been independently linked to pathophysiological states associated with epilepsy.

Experimental approach: Our study models were HEK293T cells heterologously expressing D1 or D5 receptor and CaV 3.1-3, and mouse brain slices containing the hippocampus. We used chlorpromazine (D1 /D5 inverse agonist) and a D5 receptor mutant lacking constitutive activity as experimental tools. We measured CaV 3 currents and excitability parameters using the patch-clamp technique. We completed our study with computational modelling and imaging technique.

Key results: We found a higher sensitivity to TTA-P2 (CaV 3 blocker) in CA1 pyramidal neurons obtained from chlorpromazine-treated animals compared with vehicle-treated animals. We found that CaV 3.2 and CaV 3.3-but not CaV 3.1-are targets of D5 receptor constitutive activity in HEK293T cells. Finally, we found an increased firing rate in CA1 pyramidal neurons from chlorpromazine-treated animals in comparison with vehicle-treated animals. Similar changes in firing rate were observed on a neuronal model with controlled CaV 3 currents levels.

Conclusions and implications: Native hippocampal CaV 3 and recombinant CaV 3.2-3 are sensitive to D5 receptor constitutive activity. Manipulation of D5 receptor constitutive activity could be a valuable strategy to control neuronal excitability, especially in exacerbated conditions such as epilepsy.

Keywords: CaV3.2; CaV3.3; D5 receptor; chlorpromazine; constitutive activity; hippocampus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Chlorpromazine / pharmacology
  • Dopamine*
  • Drug Inverse Agonism
  • HEK293 Cells
  • Hippocampus / metabolism
  • Humans
  • Mice
  • Neurons / metabolism
  • Potassium Channels, Calcium-Activated / metabolism
  • Receptors, Dopamine D1* / metabolism
  • Receptors, Dopamine D5 / metabolism

Substances

  • Chlorpromazine
  • Dopamine
  • Receptors, Dopamine D1
  • Receptors, Dopamine D5
  • Potassium Channels, Calcium-Activated